Changes
On July 22, 2022 at 2:34:50 PM UTC, Chimwemwe Mkandawire:
-
Added resource Unnamed resource to Malawi Integrated HIV Program Report 2020 Q2
f | 1 | { | f | 1 | { |
2 | "author": "", | 2 | "author": "", | ||
3 | "author_email": "", | 3 | "author_email": "", | ||
4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | 4 | "creator_user_id": "c64e3919-2d1c-42bf-835b-e85a6be9792c", | ||
5 | "groups": [], | 5 | "groups": [], | ||
6 | "id": "8eaeb2f0-4ee2-4b4c-8402-95e5465bf4eb", | 6 | "id": "8eaeb2f0-4ee2-4b4c-8402-95e5465bf4eb", | ||
7 | "isopen": false, | 7 | "isopen": false, | ||
8 | "license_id": "notspecified", | 8 | "license_id": "notspecified", | ||
9 | "license_title": "License not specified", | 9 | "license_title": "License not specified", | ||
10 | "maintainer": null, | 10 | "maintainer": null, | ||
11 | "maintainer_email": null, | 11 | "maintainer_email": null, | ||
12 | "metadata_created": "2022-07-22T14:33:51.535291", | 12 | "metadata_created": "2022-07-22T14:33:51.535291", | ||
n | 13 | "metadata_modified": "2022-07-22T14:33:51.535298", | n | 13 | "metadata_modified": "2022-07-22T14:34:50.510805", |
14 | "name": "malawi-integrated-hiv-program-report-2020-q2", | 14 | "name": "malawi-integrated-hiv-program-report-2020-q2", | ||
15 | "notes": "#COVID-19 Disruptions to the HIV Program \r\n\r\nThe first | 15 | "notes": "#COVID-19 Disruptions to the HIV Program \r\n\r\nThe first | ||
16 | cases of COVID-19 in Malawi were confirmed on 2nd April 2020, one week | 16 | cases of COVID-19 in Malawi were confirmed on 2nd April 2020, one week | ||
17 | before the scheduled start of integrated HIV program supervision for | 17 | before the scheduled start of integrated HIV program supervision for | ||
18 | Q1 2020. Early epidemiological models predicted rapid spread and | 18 | Q1 2020. Early epidemiological models predicted rapid spread and | ||
19 | severe impact of COVID-19 in Malawi. Fragile health services were not | 19 | severe impact of COVID-19 in Malawi. Fragile health services were not | ||
20 | well prepared to prevent infections and deal with cases. \r\n\r\nThe | 20 | well prepared to prevent infections and deal with cases. \r\n\r\nThe | ||
21 | DHA therefore decided to suspend the established quarterly supportive | 21 | DHA therefore decided to suspend the established quarterly supportive | ||
22 | supervision activity in April 2020 in\r\norder not to contribute to | 22 | supervision activity in April 2020 in\r\norder not to contribute to | ||
23 | transmission at visited health facilities and to protect staff. The | 23 | transmission at visited health facilities and to protect staff. The | ||
24 | following report is based on data collected during the following | 24 | following report is based on data collected during the following | ||
25 | supervision round in July 2020, which combined the Q1 and Q2 reporting | 25 | supervision round in July 2020, which combined the Q1 and Q2 reporting | ||
26 | periods. This combined quarterly supervision round was extended by one | 26 | periods. This combined quarterly supervision round was extended by one | ||
27 | week (13-31 July) to cope with the added workload and the service | 27 | week (13-31 July) to cope with the added workload and the service | ||
28 | disruptions. However, considerable challenges have affected the usual | 28 | disruptions. However, considerable challenges have affected the usual | ||
29 | completeness and\r\nquality of service data. \r\n\r\nThe DHA issued 3 | 29 | completeness and\r\nquality of service data. \r\n\r\nThe DHA issued 3 | ||
30 | editions of a circular to all HIV service delivery sites (on 3rd, 17th | 30 | editions of a circular to all HIV service delivery sites (on 3rd, 17th | ||
31 | April and 15th June) with specific infection prevention guidance for | 31 | April and 15th June) with specific infection prevention guidance for | ||
32 | COVID-19, and policy recommendations aimed at decongesting facilities, | 32 | COVID-19, and policy recommendations aimed at decongesting facilities, | ||
33 | and reducing travel and contact exposure for patients and health | 33 | and reducing travel and contact exposure for patients and health | ||
34 | workers. This included a temporary suspension of non-essential | 34 | workers. This included a temporary suspension of non-essential | ||
35 | services: routine scheduled viral load monitoring for stable adult | 35 | services: routine scheduled viral load monitoring for stable adult | ||
36 | patients; VMMC; active index partner tracing; new initiation of IPT | 36 | patients; VMMC; active index partner tracing; new initiation of IPT | ||
37 | and PrEP; Teen clubs and other ART support groups involving social | 37 | and PrEP; Teen clubs and other ART support groups involving social | ||
38 | gatherings. The DHA also recommended an enhanced implementation of | 38 | gatherings. The DHA also recommended an enhanced implementation of | ||
39 | 6-month ARV dispensing for almost all patient groups. As the COVID-19 | 39 | 6-month ARV dispensing for almost all patient groups. As the COVID-19 | ||
40 | impact remained much lower than initially feared, the suspended | 40 | impact remained much lower than initially feared, the suspended | ||
41 | services were successively reintroduced.\r\n\r\nThere was a noticeable | 41 | services were successively reintroduced.\r\n\r\nThere was a noticeable | ||
42 | reduction in some HIV service outputs in Q2 compared with Q1 | 42 | reduction in some HIV service outputs in Q2 compared with Q1 | ||
43 | 2020:\r\n*Total HTS outputs declined by 35%\r\n* New ART initiations | 43 | 2020:\r\n*Total HTS outputs declined by 35%\r\n* New ART initiations | ||
44 | declined by 32%\r\n* The number of blood units collected reduced by | 44 | declined by 32%\r\n* The number of blood units collected reduced by | ||
45 | 23%\r\n* The number of routine viral load samples collected reduced by | 45 | 23%\r\n* The number of routine viral load samples collected reduced by | ||
46 | 5%\r\n\r\nHowever, program reports showed no indication for increased | 46 | 5%\r\n\r\nHowever, program reports showed no indication for increased | ||
47 | ART program attrition or lower adherence compared with previous | 47 | ART program attrition or lower adherence compared with previous | ||
48 | quarters.\r\n\r\nScale-up of integrated Program performance highlights | 48 | quarters.\r\n\r\nScale-up of integrated Program performance highlights | ||
49 | by the end of June 2020\r\n* HIV services had reached the following | 49 | by the end of June 2020\r\n* HIV services had reached the following | ||
50 | number of sites:\r\no 765 static and 68 outreach HIV testing | 50 | number of sites:\r\no 765 static and 68 outreach HIV testing | ||
51 | sites.\r\no 755 (static) ART sites; 590 of these started at least one | 51 | sites.\r\no 755 (static) ART sites; 590 of these started at least one | ||
52 | pregnant or breastfeeding\r\nwoman.\r\no 691 sites with HIV-exposed | 52 | pregnant or breastfeeding\r\nwoman.\r\no 691 sites with HIV-exposed | ||
53 | children in follow-up.\r\n\u2022 634,564 persons were tested for HIV | 53 | children in follow-up.\r\n\u2022 634,564 persons were tested for HIV | ||
54 | and received their results; 107,507 (17%)\r\naccessed HIV testing for | 54 | and received their results; 107,507 (17%)\r\naccessed HIV testing for | ||
55 | the first time; 527,057 (80%) were repeat testers and 21,049\r\nMalawi | 55 | the first time; 527,057 (80%) were repeat testers and 21,049\r\nMalawi | ||
56 | Integrated HIV Program Report (April-June2020) Page | 4\r\n(4%) of | 56 | Integrated HIV Program Report (April-June2020) Page | 4\r\n(4%) of | ||
57 | these received confirmatory testing (after having tested positive in | 57 | these received confirmatory testing (after having tested positive in | ||
58 | the past).\r\n18,882 (3.1%) clients received a positive result for the | 58 | the past).\r\n18,882 (3.1%) clients received a positive result for the | ||
59 | first time1.\r\n\u2022 A total of 63,600 people received 105,211 | 59 | first time1.\r\n\u2022 A total of 63,600 people received 105,211 | ||
60 | self-test kits for either primary or\r\nsecondary use.\r\n\u2022 | 60 | self-test kits for either primary or\r\nsecondary use.\r\n\u2022 | ||
61 | 16,049 (94%) of 17,095 blood units collected were screened for (at | 61 | 16,049 (94%) of 17,095 blood units collected were screened for (at | ||
62 | least) HIV,\r\nhepatitis B and syphilis.\r\n\u2022 162,127 (99%) of | 62 | least) HIV,\r\nhepatitis B and syphilis.\r\n\u2022 162,127 (99%) of | ||
63 | 164,354 women at ANC had their HIV status ascertained;\r\n10,695 (7%) | 63 | 164,354 women at ANC had their HIV status ascertained;\r\n10,695 (7%) | ||
64 | of these were HIV positive. 138,394 (95%) of 145,981 at maternity | 64 | of these were HIV positive. 138,394 (95%) of 145,981 at maternity | ||
65 | had\r\ntheir HIV status ascertained 10,075 (7%) of these were HIV | 65 | had\r\ntheir HIV status ascertained 10,075 (7%) of these were HIV | ||
66 | positive.\r\n\u2022 18,804 patients started ART this quarter; 88% were | 66 | positive.\r\n\u2022 18,804 patients started ART this quarter; 88% were | ||
67 | classified as asymptomatic / in\r\nWHO stage 1 and started under the | 67 | classified as asymptomatic / in\r\nWHO stage 1 and started under the | ||
68 | \u201cTest & Treat\u201d policy.\r\n\u2022 846,164 patients were alive | 68 | \u201cTest & Treat\u201d policy.\r\n\u2022 846,164 patients were alive | ||
69 | and on ART by end of June 2020.2 This means that 79%\r\nof the | 69 | and on ART by end of June 2020.2 This means that 79%\r\nof the | ||
70 | estimated 1,072,534 HIV positive population was on ART. 3 ART coverage | 70 | estimated 1,072,534 HIV positive population was on ART. 3 ART coverage | ||
71 | was\r\n75% (44,355/ 58,752) for children4 and 79% (801,909 / | 71 | was\r\n75% (44,355/ 58,752) for children4 and 79% (801,909 / | ||
72 | 1,013,782) for adults.\r\n\u2022 76,921 (94%) of viral load results | 72 | 1,013,782) for adults.\r\n\u2022 76,921 (94%) of viral load results | ||
73 | from routine monitoring were <1000 copies/ml.\r\nViral suppression | 73 | from routine monitoring were <1000 copies/ml.\r\nViral suppression | ||
74 | rates for routine samples among children (0-14 years) and | 74 | rates for routine samples among children (0-14 years) and | ||
75 | adults\r\n(15+ years) were 71% and 95%, respectively.\r\n\u2022 71% of | 75 | adults\r\n(15+ years) were 71% and 95%, respectively.\r\n\u2022 71% of | ||
76 | adults and 76% of children were retained alive on ART at 12 months | 76 | adults and 76% of children were retained alive on ART at 12 months | ||
77 | after\r\ninitiation.5\r\n\u2022 Out of 811,825 patients on first line | 77 | after\r\ninitiation.5\r\n\u2022 Out of 811,825 patients on first line | ||
78 | adult ART 34,256 (4%) were on TDF/3TC/EFV\r\nand 752,779 (94%) had | 78 | adult ART 34,256 (4%) were on TDF/3TC/EFV\r\nand 752,779 (94%) had | ||
79 | transitioned to TDF/3TC/DTG.\r\n\u2022 11,876 6 (>99%) of an estimated | 79 | transitioned to TDF/3TC/DTG.\r\n\u2022 11,876 6 (>99%) of an estimated | ||
80 | 10,3643 HIV infected pregnant women in Malawi\r\nwere on ART this | 80 | 10,3643 HIV infected pregnant women in Malawi\r\nwere on ART this | ||
81 | quarter. 9,943 (84%) of these were already on ART when | 81 | quarter. 9,943 (84%) of these were already on ART when | ||
82 | getting\r\npregnant and 2,293 (24%) started ART during | 82 | getting\r\npregnant and 2,293 (24%) started ART during | ||
83 | pregnancy/delivery.\r\n\u2022 An additional 798 breastfeeding women | 83 | pregnancy/delivery.\r\n\u2022 An additional 798 breastfeeding women | ||
84 | started ART in WHO stage 1 or 2.\r\n\u2022 76% and 70% of women | 84 | started ART in WHO stage 1 or 2.\r\n\u2022 76% and 70% of women | ||
85 | started while pregnant or breastfeeding were retained on\r\nART at 6 | 85 | started while pregnant or breastfeeding were retained on\r\nART at 6 | ||
86 | and 12 months after initiation, respectively.\r\n\u2022 9,112 (7%) of | 86 | and 12 months after initiation, respectively.\r\n\u2022 9,112 (7%) of | ||
87 | infants discharged alive from maternity were known to be | 87 | infants discharged alive from maternity were known to be | ||
88 | HIV\r\nexposed, 8,808 (97%) of these received ARV prophylaxis | 88 | HIV\r\nexposed, 8,808 (97%) of these received ARV prophylaxis | ||
89 | (nevirapine).\r\nA total of 12,413 HIV exposed children were newly | 89 | (nevirapine).\r\nA total of 12,413 HIV exposed children were newly | ||
90 | enrolled for follow-up this\r\nquarter; 10,417 (84%) of these were | 90 | enrolled for follow-up this\r\nquarter; 10,417 (84%) of these were | ||
91 | enrolled before age 2 months.\r\n\u2022 Out of the total 1,072,534 | 91 | enrolled before age 2 months.\r\n\u2022 Out of the total 1,072,534 | ||
92 | estimated PLHIV by end June 2020:\r\no An estimated 91% of PLHIV knew | 92 | estimated PLHIV by end June 2020:\r\no An estimated 91% of PLHIV knew | ||
93 | their status (diagnosed)", | 93 | their status (diagnosed)", | ||
n | 94 | "num_resources": 0, | n | 94 | "num_resources": 1, |
95 | "num_tags": 10, | 95 | "num_tags": 10, | ||
96 | "organization": { | 96 | "organization": { | ||
97 | "approval_status": "approved", | 97 | "approval_status": "approved", | ||
98 | "created": "2021-10-14T11:02:35.234558", | 98 | "created": "2021-10-14T11:02:35.234558", | ||
99 | "description": "The Department of HIV & AIDS (DHA) was established | 99 | "description": "The Department of HIV & AIDS (DHA) was established | ||
100 | in 2001, initially as a unit in the Department of Clinical Services, | 100 | in 2001, initially as a unit in the Department of Clinical Services, | ||
101 | to coordinate the biomedical HIV Program in Malawi. The department now | 101 | to coordinate the biomedical HIV Program in Malawi. The department now | ||
102 | carries responsibility for various HIV related programs including: | 102 | carries responsibility for various HIV related programs including: | ||
103 | sexually transmitted infections (STIs), prevention of mother to child | 103 | sexually transmitted infections (STIs), prevention of mother to child | ||
104 | transmission of HIV (PMTCT), and national voluntary male medical | 104 | transmission of HIV (PMTCT), and national voluntary male medical | ||
105 | circumcision program (VMMC). All these HIV program sub-sections are | 105 | circumcision program (VMMC). All these HIV program sub-sections are | ||
106 | linked to one robust monitoring and evaluation sub-section in the HIV | 106 | linked to one robust monitoring and evaluation sub-section in the HIV | ||
107 | and AIDS Department which technically operates under the Central | 107 | and AIDS Department which technically operates under the Central | ||
108 | Monitoring and Evaluation Department (CMED) of the Ministry of | 108 | Monitoring and Evaluation Department (CMED) of the Ministry of | ||
109 | Health.", | 109 | Health.", | ||
110 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 110 | "id": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
111 | "image_url": | 111 | "image_url": | ||
112 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | 112 | 2022-04-18-074318.527302WhatsApp-Image-2022-04-18-at-9.42.07-AM.jpeg", | ||
113 | "is_organization": true, | 113 | "is_organization": true, | ||
114 | "name": "dha", | 114 | "name": "dha", | ||
115 | "state": "active", | 115 | "state": "active", | ||
116 | "title": "Department of HIV & AIDS and Viral Hepatitis", | 116 | "title": "Department of HIV & AIDS and Viral Hepatitis", | ||
117 | "type": "organization" | 117 | "type": "organization" | ||
118 | }, | 118 | }, | ||
119 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | 119 | "owner_org": "ca6a5fbb-31b1-44f8-9319-5da56d75a55b", | ||
120 | "private": false, | 120 | "private": false, | ||
121 | "program_area": "Care and Treatment", | 121 | "program_area": "Care and Treatment", | ||
122 | "relationships_as_object": [], | 122 | "relationships_as_object": [], | ||
123 | "relationships_as_subject": [], | 123 | "relationships_as_subject": [], | ||
t | 124 | "resources": [], | t | 124 | "resources": [ |
125 | { | ||||
126 | "cache_last_updated": null, | ||||
127 | "cache_url": null, | ||||
128 | "created": "2022-07-22T14:34:50.549344", | ||||
129 | "description": "", | ||||
130 | "format": "PDF", | ||||
131 | "hash": "", | ||||
132 | "id": "8c9798b4-2ce2-4432-80c1-99e46da81781", | ||||
133 | "last_modified": "2022-07-22T14:34:50.498103", | ||||
134 | "lfs_prefix": | ||||
135 | "dha/malawi-integrated-hiv-program-report-2020-q2", | ||||
136 | "metadata_modified": "2022-07-22T14:34:50.524694", | ||||
137 | "mimetype": "application/pdf", | ||||
138 | "mimetype_inner": null, | ||||
139 | "name": "", | ||||
140 | "package_id": "8eaeb2f0-4ee2-4b4c-8402-95e5465bf4eb", | ||||
141 | "position": 0, | ||||
142 | "resource_type": null, | ||||
143 | "sha256": | ||||
144 | "4489b1563b51b926d9229cea9eab3232311ccf8224f1744d9fb4215ad83d492e", | ||||
145 | "size": 4791972, | ||||
146 | "state": "active", | ||||
147 | "url": | ||||
148 | e46da81781/download/malawi_integrated_hiv_program_report_2020-q2.pdf", | ||||
149 | "url_type": "upload" | ||||
150 | } | ||||
151 | ], | ||||
125 | "state": "draft", | 152 | "state": "draft", | ||
126 | "tags": [ | 153 | "tags": [ | ||
127 | { | 154 | { | ||
128 | "display_name": "ART", | 155 | "display_name": "ART", | ||
129 | "id": "5edd9998-b4ff-40a1-9431-2a7b5b733d4d", | 156 | "id": "5edd9998-b4ff-40a1-9431-2a7b5b733d4d", | ||
130 | "name": "ART", | 157 | "name": "ART", | ||
131 | "state": "active", | 158 | "state": "active", | ||
132 | "vocabulary_id": null | 159 | "vocabulary_id": null | ||
133 | }, | 160 | }, | ||
134 | { | 161 | { | ||
135 | "display_name": "HTC", | 162 | "display_name": "HTC", | ||
136 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | 163 | "id": "6a53fcf5-e774-4295-b9c3-32da8b896f9b", | ||
137 | "name": "HTC", | 164 | "name": "HTC", | ||
138 | "state": "active", | 165 | "state": "active", | ||
139 | "vocabulary_id": null | 166 | "vocabulary_id": null | ||
140 | }, | 167 | }, | ||
141 | { | 168 | { | ||
142 | "display_name": "PMTCT-ART", | 169 | "display_name": "PMTCT-ART", | ||
143 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | 170 | "id": "83bf82ef-383c-46e2-a80c-f3431b3f99e2", | ||
144 | "name": "PMTCT-ART", | 171 | "name": "PMTCT-ART", | ||
145 | "state": "active", | 172 | "state": "active", | ||
146 | "vocabulary_id": null | 173 | "vocabulary_id": null | ||
147 | }, | 174 | }, | ||
148 | { | 175 | { | ||
149 | "display_name": "STI", | 176 | "display_name": "STI", | ||
150 | "id": "94fb1475-9b2d-40af-b19d-c6463a0dd66d", | 177 | "id": "94fb1475-9b2d-40af-b19d-c6463a0dd66d", | ||
151 | "name": "STI", | 178 | "name": "STI", | ||
152 | "state": "active", | 179 | "state": "active", | ||
153 | "vocabulary_id": null | 180 | "vocabulary_id": null | ||
154 | }, | 181 | }, | ||
155 | { | 182 | { | ||
156 | "display_name": "Viral load", | 183 | "display_name": "Viral load", | ||
157 | "id": "141b4c03-db16-4d5c-9d36-82cc40db0a35", | 184 | "id": "141b4c03-db16-4d5c-9d36-82cc40db0a35", | ||
158 | "name": "Viral load", | 185 | "name": "Viral load", | ||
159 | "state": "active", | 186 | "state": "active", | ||
160 | "vocabulary_id": null | 187 | "vocabulary_id": null | ||
161 | }, | 188 | }, | ||
162 | { | 189 | { | ||
163 | "display_name": "anc", | 190 | "display_name": "anc", | ||
164 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | 191 | "id": "1e47aae6-8e3d-41e7-9b1a-778af0d2f23a", | ||
165 | "name": "anc", | 192 | "name": "anc", | ||
166 | "state": "active", | 193 | "state": "active", | ||
167 | "vocabulary_id": null | 194 | "vocabulary_id": null | ||
168 | }, | 195 | }, | ||
169 | { | 196 | { | ||
170 | "display_name": "blood safety", | 197 | "display_name": "blood safety", | ||
171 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | 198 | "id": "24fd7907-18be-4ad1-80ad-ba65da6a9707", | ||
172 | "name": "blood safety", | 199 | "name": "blood safety", | ||
173 | "state": "active", | 200 | "state": "active", | ||
174 | "vocabulary_id": null | 201 | "vocabulary_id": null | ||
175 | }, | 202 | }, | ||
176 | { | 203 | { | ||
177 | "display_name": "hiv", | 204 | "display_name": "hiv", | ||
178 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | 205 | "id": "43013fde-ebf4-470e-9e5d-1a3aa939d404", | ||
179 | "name": "hiv", | 206 | "name": "hiv", | ||
180 | "state": "active", | 207 | "state": "active", | ||
181 | "vocabulary_id": null | 208 | "vocabulary_id": null | ||
182 | }, | 209 | }, | ||
183 | { | 210 | { | ||
184 | "display_name": "maternity", | 211 | "display_name": "maternity", | ||
185 | "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", | 212 | "id": "cd2b6dc5-5d1f-4a03-91da-9a279e193ed2", | ||
186 | "name": "maternity", | 213 | "name": "maternity", | ||
187 | "state": "active", | 214 | "state": "active", | ||
188 | "vocabulary_id": null | 215 | "vocabulary_id": null | ||
189 | }, | 216 | }, | ||
190 | { | 217 | { | ||
191 | "display_name": "viral load", | 218 | "display_name": "viral load", | ||
192 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | 219 | "id": "e385a0a4-1722-431f-a657-f9616a14bf6f", | ||
193 | "name": "viral load", | 220 | "name": "viral load", | ||
194 | "state": "active", | 221 | "state": "active", | ||
195 | "vocabulary_id": null | 222 | "vocabulary_id": null | ||
196 | } | 223 | } | ||
197 | ], | 224 | ], | ||
198 | "title": "Malawi Integrated HIV Program Report 2020 Q2", | 225 | "title": "Malawi Integrated HIV Program Report 2020 Q2", | ||
199 | "type": "dataset", | 226 | "type": "dataset", | ||
200 | "url": null, | 227 | "url": null, | ||
201 | "version": null, | 228 | "version": null, | ||
202 | "year": "2020" | 229 | "year": "2020" | ||
203 | } | 230 | } |